# Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

> **NCT05037396** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9457 (actual)

## Conditions studied

- Age-related Macular Degeneration (AMD)

## Interventions

- **DRUG:** Brolucizumab

## Key facts

- **NCT ID:** NCT05037396
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-05
- **Primary completion:** 2020-08-01
- **Final completion:** 2020-08-01
- **Target enrollment:** 9457 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05037396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05037396, "Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05037396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*